{"pmid":32343686,"title":"Pandemic responses: Planning to neutralize SARS-CoV-2 and prepare for future outbreaks.","text":["Pandemic responses: Planning to neutralize SARS-CoV-2 and prepare for future outbreaks.","The PLOS Medicine Editors discuss the current SARS-CoV-2 outbreak and implications for global health.","PLoS Med","32343686"],"abstract":["The PLOS Medicine Editors discuss the current SARS-CoV-2 outbreak and implications for global health."],"journal":"PLoS Med","date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343686","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1371/journal.pmed.1003123","topics":["Prevention"],"weight":1,"_version_":1665351883931254784,"score":8.574329,"similar":[{"pmid":32226289,"pmcid":"PMC7098029","title":"Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.","text":["Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.","A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the SARS-CoV-2 show high homology with that of SARS-CoV. Current efforts are focusing on development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2 will be greatly important therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19). Herein, the host immune responses against SARS-CoV discussed in this review provide implications for developing NAbs and understanding clinical interventions against SARS-CoV-2. Further, we describe the benefits, challenges and considerations of NAbs against SARS-CoV-2. Although many challenges exist, NAbs still offer a therapeutic option to control the current pandemic and the possible re-emergence of the virus in the future, and their development therefore remains a high priority.","Int J Biol Sci","Zhou, Guangyu","Zhao, Qi","32226289"],"abstract":["A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the SARS-CoV-2 show high homology with that of SARS-CoV. Current efforts are focusing on development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2 will be greatly important therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19). Herein, the host immune responses against SARS-CoV discussed in this review provide implications for developing NAbs and understanding clinical interventions against SARS-CoV-2. Further, we describe the benefits, challenges and considerations of NAbs against SARS-CoV-2. Although many challenges exist, NAbs still offer a therapeutic option to control the current pandemic and the possible re-emergence of the virus in the future, and their development therefore remains a high priority."],"journal":"Int J Biol Sci","authors":["Zhou, Guangyu","Zhao, Qi"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32226289","week":"202014|Mar 30 - Apr 05","doi":"10.7150/ijbs.45123","keywords":["covid-19","neutralizing antibody","sars-cov-2","severe acute respiratory syndrome"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664640912693657600,"score":57.663445},{"pmid":32306790,"title":"Preparing Hospitals for Coronavirus (COVID-19).","text":["Preparing Hospitals for Coronavirus (COVID-19).","The COVID-19 virus has generated worldwide attention due to its recent discovery and rapid spread. There are currently almost 2 million confirmed cases of COVID-19 worldwide of which about 117,000 patients have died (WHO). March has seen fast rises in the number of cases in Italy, Spain and the US, which has focused the need for countries medical systems to contain the virus and prevent its spread. Currently the US has over 500,000 cases, the largest number of any country in the world.This has resulted in hospitals around the world producing action plans to isolate and treat suspected COVID-19 patients. In this exclusive interview for Hospital Practice Dr. Edward Jasper of Jefferson Hospitals discusses how his hospital has dealt with outbreaks in the past as well as how it is now preparing for COVID-19.Interview with Edward Jasper by Mike Gregg, Editor.","Hosp Pract (1995)","Jasper, Edward","32306790"],"abstract":["The COVID-19 virus has generated worldwide attention due to its recent discovery and rapid spread. There are currently almost 2 million confirmed cases of COVID-19 worldwide of which about 117,000 patients have died (WHO). March has seen fast rises in the number of cases in Italy, Spain and the US, which has focused the need for countries medical systems to contain the virus and prevent its spread. Currently the US has over 500,000 cases, the largest number of any country in the world.This has resulted in hospitals around the world producing action plans to isolate and treat suspected COVID-19 patients. In this exclusive interview for Hospital Practice Dr. Edward Jasper of Jefferson Hospitals discusses how his hospital has dealt with outbreaks in the past as well as how it is now preparing for COVID-19.Interview with Edward Jasper by Mike Gregg, Editor."],"journal":"Hosp Pract (1995)","authors":["Jasper, Edward"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32306790","week":"202017|Apr 20 - Apr 26","doi":"10.1080/21548331.2020.1757337","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Italy","Spain","US","US"],"countries":["Spain","United States","Italy"],"countries_codes":["ESP|Spain","USA|United States","ITA|Italy"],"_version_":1664632501407055872,"score":55.410122},{"pmid":32249063,"title":"Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.","text":["Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.","Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs.","Trends Immunol","Jiang, Shibo","Hillyer, Christopher","Du, Lanying","32249063"],"abstract":["Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs."],"journal":"Trends Immunol","authors":["Jiang, Shibo","Hillyer, Christopher","Du, Lanying"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32249063","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.it.2020.03.007","keywords":["MERS-CoV","SARS-CoV","SARS-CoV-2","human coronaviruses","neutralizing antibodies"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352136198520832,"score":54.263653},{"pmid":32202513,"title":"Changing the editorial process at JCI and JCI Insight in response to the COVID-19 pandemic.","text":["Changing the editorial process at JCI and JCI Insight in response to the COVID-19 pandemic.","The editors of JCI and JCI Insight are revisiting our editorial processes in light of the strain that the COVID-19 pandemic places on the worldwide scientific community. Here, we discuss adjustments to our decision framework in light of restrictions placed on laboratory working conditions for many of our authors.","J Clin Invest","Ahima, Rexford S","Jackson, Sarah","Casadevall, Arturo","Semenza, Gregg L","Tomaselli, Gordon","Collins, Kathleen L","Lieberman, Andrew P","Martin, Donna M","Reddy, Pavan","32202513"],"abstract":["The editors of JCI and JCI Insight are revisiting our editorial processes in light of the strain that the COVID-19 pandemic places on the worldwide scientific community. Here, we discuss adjustments to our decision framework in light of restrictions placed on laboratory working conditions for many of our authors."],"journal":"J Clin Invest","authors":["Ahima, Rexford S","Jackson, Sarah","Casadevall, Arturo","Semenza, Gregg L","Tomaselli, Gordon","Collins, Kathleen L","Lieberman, Andrew P","Martin, Donna M","Reddy, Pavan"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32202513","week":"202013|Mar 23 - Mar 29","doi":"10.1172/JCI138305","source":"PubMed","topics":["General Info"],"weight":1,"_version_":1664639760415588353,"score":47.012135},{"pmid":32259394,"title":"COVID-19, chronicle of an expected pandemic.","text":["COVID-19, chronicle of an expected pandemic.","What is COVID-19? What are the causes, parameters, and effects of this disease? What are the short- and long-term prospects? Philippe Sansonetti, Infectious disease specialist and Chief Editor of EMBO Molecular Medicine, explains why the fate of the epidemic is in our hands.","EMBO Mol Med","Sansonetti, Philippe","32259394"],"abstract":["What is COVID-19? What are the causes, parameters, and effects of this disease? What are the short- and long-term prospects? Philippe Sansonetti, Infectious disease specialist and Chief Editor of EMBO Molecular Medicine, explains why the fate of the epidemic is in our hands."],"journal":"EMBO Mol Med","authors":["Sansonetti, Philippe"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259394","week":"202015|Apr 06 - Apr 12","doi":"10.15252/emmm.202012463","source":"PubMed","weight":0,"_version_":1664640769786380288,"score":45.296253}]}